CAN-FITE BIOPHARMA LTD SPONSORE

Codice
canf
Risorse esterne
Opinione della community
Prezzo Variazione Volume
1.7899 +0.4 €
(+28.78%)
13237
P/E Obiettivo ad 1anno
0 6 €

Compra - Vendi

0
Tutte le tue transazioni per questo titolo

Devi effettuare l'accesso


Grafico

Altri utenti che hanno investito

Transations in last week
Buy: 17
Sell : 8

Matteo Berci Simone Bonzanini edoardo Federico Borghi LucaMazzu91

Commenti


Notizie

Pluristem raises $15m, Can-Fite raises $5m - Globes

Two biomed companies, Pluristem Therapeutics Ltd. (Nasdaq:PSTI; TASE: PLTR) and Can-Fite BioPharma Ltd. (TASE:CFBI), announced financing rounds at the end of last week. Pluristem raised $15 million, after enlarging its planned offering, while Can-Fite ...altro » Leggi

Can-Fite BioPharma shares tumble as glaucoma drug trial fails to meet goals - MarketWatch

Shares of Israeli biotech Can-Fite BioPharma Ltd. CANF, +0.56% tumbled 25% in premarket trade Tuesday, after the company said a trial of a glaucoma treatment failed to meet its main goal. The company said a phase II trial conducted by it's subsidiary ... Leggi

1.79 - MarketWatch

Can-Fite Biopharma Ltd. ADR. Watchlist CreateCANFAlert. Closed. Last Updated: Jul 25, 2017 3:57 p.m. EDT Delayed quote .... NASH event today to inform investors. Oct. 5, 2016 at 11:21 a.m. ET; on Seeking Alpha. Sponsored ... Historical and current end ... Leggi

Pipeline of Psoriasis Market Covering 140 Companies Reviewed for H1 2016 - MarketWatch

Companies discussed in this Psoriasis Pipeline Review, H1 2016 report include 3SBio Inc., 4SC AG, Abeome Corporation, AbGenomics International, Inc., ADC Therapeutics Sarl, Addex Therapeutics Ltd, Advinus Therapeutics Ltd., Affibody AB, Ajinomoto ...altro » Leggi

The Plaque Psoriasis (Psoriasis Vulgaris) Pipeline 2016 Market Report - MarketWatch

... Bristol-Myers Squibb Company, Can-Fite BioPharma Ltd., Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., Clonz Biotech Private Limited, Coherus BioSciences, Inc., Delenex Therapeutics AG, Eli Lilly and Company, Epirus Biopharmaceuticals ...altro » Leggi

CANF: Take Multiple Shots on Goal With Can-Fite BioPharma - Investorplace.com

The Life Sciences Report interviews Pnina Fishman, the scientific founder of Can-Fite BioPharma Ltd (ADR). can fite biopharma-canf-stock-185 The Life Sciences Report: Can-Fite BioPharma Ltd (ADR) (NYSEMKT:CANF) has three candidates, two in the ...altro » Leggi

BlackBerry (BBRY) Secures New Crisis Communication Software Customers in Australia & New Zealand - StreetInsider.com

BlackBerry Limited (NASDAQ: BBRY) today announced Bank of New Zealand (BNZ), one of the country's largest banks, is one of the latest customers in the region to deploy BlackBerry AtHoc, the company's industry-leading, secure crisis communications ...altro » Leggi

Zacks Initiates on Pulmatrix (NASDAQ:PULM) - Zacks Small Cap Research (press release)

Lactose blends have limited delivery efficiency, are flow rate dependent, and can cause significant side effects based on high throat deposition (i.e. much of the drug deposited in the throat instead of the lungs). ..... In early 2016 a marketing study ...altro » Leggi

Merck (MRK) Announces FDA Approval for KEYTRUDA to Treat Patients with Refractory cHL or Relapses - StreetInsider.com

“For the patients with classical Hodgkin lymphoma who are not cured with existing treatments, there are limited options, and treating their disease becomes more challenging,” said Dr. Craig Moskowitz, clinical director, division of hematologic oncology ...altro » Leggi

RepliCel (RP.V) Should Benefit From Renewed Investor Focus, Sweeping Legislation On Cell Therapy - Zacks Small Cap Research (press release)

The combination of renewed investor attention and sweeping legislation should make it a good year for many publicly-traded regenerative medicine companies. One such company that looks very well-positioned to benefit from the ... In Japan, biopharma ...altro » Leggi